These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8759888)

  • 1. Second transplantation using allogeneic peripheral blood stem cells in a beta-thalassaemia major patient featuring stable mixed chimaerism.
    Or R; Kapelushnik J; Naparstek E; Nagler A; Filon D; Oppenheim A; Amar A; Aker M; Samuel S; Slavin S
    Br J Haematol; 1996 Aug; 94(2):285-7. PubMed ID: 8759888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of chimaerism in thalassaemic children undergoing stem cell transplantation.
    Amrolia PJ; Vulliamy T; Vassiliou G; Lawson S; Bryon J; Kaeda J; Dokal I; Johnston R; Veys P; Darbyshire P; Roberts IA
    Br J Haematol; 2001 Jul; 114(1):219-25. PubMed ID: 11472371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling.
    Lisini D; Zecca M; Giorgiani G; Montagna D; Cristantielli R; Labirio M; Grignani P; Previderè C; Di Cesare-Merlone A; Amendola G; Bergami E; Mastronuzzi A; Maccario R; Locatelli F
    Haematologica; 2008 Dec; 93(12):1859-67. PubMed ID: 18945748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second transplant for a thalassemia patient after graft rejection: with immunosuppression and allogeneic peripheral blood stem cell.
    Li CK; Shing MM; Chik KW; Lee V; Tsang KS; Yuen PM
    Pediatr Hematol Oncol; 2002 Jun; 19(4):267-71. PubMed ID: 12051594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disparate lympho-erythroid donor to recipient chimaerism in a beta(0)-thalassaemia bone marrow transplant recipient with red cell indices indicative of apparent full engraftment.
    Weinberg RS; Vlachos A; Najfeld V; Galperin Y; Scalise A; Fruchtman S; Lipton JM
    Br J Haematol; 1997 Oct; 99(1):61-3. PubMed ID: 9359504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Allogeneic hematopoietic stem cell transplantation for beta-thalassemia major].
    Li CF; He YL; Zhang YM; Yang M; Wu XD; Bai J
    Zhonghua Xue Ye Xue Za Zhi; 2003 Apr; 24(4):174-6. PubMed ID: 12864945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for beta-thalassemia major.
    Aker M; Kapelushnik J; Pugatsch T; Naparstek E; Ben-Neria S; Yehuda O; Amar A; Nagler A; Slavin S; Or R
    J Pediatr Hematol Oncol; 1998; 20(2):145-8. PubMed ID: 9544166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of mixed chimaerism and clinical outcome in 101 patients after myeloablative conditioning regimens and allogeneic stem cell transplantation.
    Wäsch R; Bertz H; Kunzmann R; Finke J
    Br J Haematol; 2000 Jun; 109(4):743-50. PubMed ID: 10929024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow transplantation for beta-thalassaemia major: the UK experience in two paediatric centres.
    Lawson SE; Roberts IA; Amrolia P; Dokal I; Szydlo R; Darbyshire PJ
    Br J Haematol; 2003 Jan; 120(2):289-95. PubMed ID: 12542489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor immune reconstitution after four or five major HLA antigens mismatched T cell-depleted allogeneic and autologous stem cell transplantation.
    Mattsson J; Uzunel M; Remberger M; Tammik L; Omazic B; Levitsky V; Zou JZ; Hentschke P; Ringdén O
    Clin Exp Immunol; 2001 Jan; 123(1):162-9. PubMed ID: 11168014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paediatric allogeneic bone marrow transplantation for homozygous beta-thalassaemia, the Dutch experience.
    Ball LM; Lankester AC; Giordano PC; van Weel MH; Harteveld CL; Bredius RG; Smiers FJ; Egeler RM; Vossen JM
    Bone Marrow Transplant; 2003 Jun; 31(12):1081-7. PubMed ID: 12796787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
    Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic bone marrow transplantation: relation between chimaerism and immunity.
    Vossen J
    Verh K Acad Geneeskd Belg; 1998; 60(2):111-43; discussion 143-5. PubMed ID: 9703764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome.
    Ueno NT; Anagnostopoulos A; Rondón G; Champlin RE; Mikhailova N; Pankratova OS; Zoubarovskaya LS; Semenova EV; Afanasyev BV; O'Brien S; Andreeff M; Zaritskey AY
    Br J Haematol; 2002 Oct; 119(1):131-4. PubMed ID: 12358917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
    Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Full chimerism in nonmyeloablative stem cell transplantation in a beta-thalassemia major patient (class 3 Lucarelli).
    Hongeng S; Chuansumrit A; Hathirat P; Rerkamnuaychoke B; Chaisiripoomkere W; Jootar S
    Bone Marrow Transplant; 2002 Sep; 30(6):409-10. PubMed ID: 12235528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative serial quantitative measurements of chimaerism following unmanipulated allogeneic transplantation of peripheral blood stem cells and bone marrow.
    Miflin G; Stainer CJ; Carter GI; Byrne JL; Haynes AP; Russell NH
    Br J Haematol; 1999 Nov; 107(2):429-40. PubMed ID: 10583237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantation.
    Novotny JR; Rosenthal C; Elmaagacli AH; Dürig J; Beelen DW; Dührsen U
    Eur J Haematol; 2004 Jul; 73(1):1-9. PubMed ID: 15182331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent donor chimaerism is consistent with disease-free survival following BMT for chronic myeloid leukaemia.
    Gardiner N; Lawler M; O'Riordan J; DeArce M; Humphries P; McCann SR
    Bone Marrow Transplant; 1997 Aug; 20(3):235-41. PubMed ID: 9257892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow transplantation combined with mesenchymal stem cells induces immune tolerance without cytotoxic conditioning.
    Wang Y; Liu J; Xu C; Zhang W; Bai L; Li N; Liu Y; Wang Y; Su Y; Hu D
    J Surg Res; 2011 Nov; 171(1):e123-31. PubMed ID: 21920556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.